WHO members urged to delink R&D from cancer medicine

Members of the World Health Organisation (WHO) have been urged to delink the costs of research and development (R&D) from the prices of cancer medicines. 

A number of civil society organisations and health specialists have sent a letter to delegates at the annual World Health Assembly and member states have debated the issue and are yet to come to a decision.

As part of the World Health Assembly later this month, a resolution on cancer is expected after a discussion in January at the World Health Organisation Executive Board, where there was no conclusion met. 

The letter reads: “None of the 56 novel cancer medicines approved by the US FDA (Food and Drug Administration) from 2010 to 2016 are included in the WHO Model List of Essential Medicines (EML)”.

It adds that many of the drugs are not reimbursed in many countries as a result of their price, with even high-income areas finding them unaffordable. ADNFCR-2094-ID-801835770-ADNFCR